Alzheimer's disease: future drug development and the blood-brain barrier

被引：22

作者：

Pardridge, William M. ^{[1
]}

机构：

[1] Univ Calif Los Angeles, Los Angeles, CA 90032 USA

来源：

EXPERT OPINION ON INVESTIGATIONAL DRUGS | 2019年 / 28卷 / 07期

关键词：

Blood-brain barrier; CSF; therapeutic antibody; bispecific antibody; TRANSFERRIN RECEPTOR; AMYLOID-BETA; ANTIBODY; ERYTHROPOIETIN; DELIVERY; PROTEIN; ALPHA; MICE; TNF; CSF;

D O I：

10.1080/13543784.2019.1627325

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

[No abstract available]

引用

页码：569 / 572

页数：4

共 31 条

[11] ABBY A phase 2 randomized trial of crenezumab in mild to moderate Alzheimer disease [J].

Cummings, Jeffrey L. ;

Cohen, Sharon ;

van Dyck, Christopher H. ;

Brody, Mark ;

Curtis, Craig ;

Cho, William ;

Ward, Michael ;

Friesenhahn, Michel ;

Rabe, Christina ;

Brunstein, Flavia ;

Quartino, Angelica ;

Honigberg, Lee A. ;

Fuji, Reina N. ;

Clayton, David ;

Mortensen, Deborah ;

Ho, Carole ;

Paul, Robert .

NEUROLOGY, 2018, 90 (21) :E1889-E1897

[12] Erythropoietin therapy for acute stroke is both safe and beneficial [J].

Ehrenreich, H ;

Hasselblatt, M ;

Dembowski, C ;

Cepek, L ;

Lewczuk, P ;

Stiefel, M ;

Rustenbeck, HH ;

Breiter, N ;

Jacob, S ;

Knerlich, F ;

Bohn, M ;

Poser, W ;

Rüther, E ;

Kochen, M ;

Gefeller, O ;

Gleiter, C ;

Wessel, TC ;

De Ryck, M ;

Itri, L ;

Prange, H ;

Cerami, A ;

Brines, M ;

Sirén, AL .

MOLECULAR MEDICINE, 2002, 8 (08) :495-505

[13] Fluids and barriers of the CNS establish immune privilege by confining immune surveillance to a two-walled castle moat surrounding the CNS castle [J].

Engelhardt B. ;

Coisne C. .

Fluids and Barriers of the CNS, 8 (1)

[14] Neurocognitive and somatic stabilization in pediatric patients with severe Mucopolysaccharidosis Type I after 52 weeks of intravenous brain-penetrating insulin receptor antibody-iduronidase fusion protein (valanafusp alpha): an open label phase 1-2 trial [J].

Giugliani, Roberto ;

Giugliani, Luciana ;

Poswar, Fabiano de Oliveira ;

Donis, Karina Carvalho ;

Dalla Corte, Amauri ;

Schmidt, Mathias ;

Boado, Ruben J. ;

Nestrasil, Igor ;

Nguyen, Carol ;

Chen, Steven ;

Pardridge, William M. .

ORPHANET JOURNAL OF RARE DISEASES, 2018, 13

[15] ALZHEIMERS-DISEASE - INITIAL REPORT OF THE PURIFICATION AND CHARACTERIZATION OF A NOVEL CEREBROVASCULAR AMYLOID PROTEIN [J].

GLENNER, GG ;

WONG, CW .

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1984, 120 (03) :885-890

[16] Focused Ultrasound Enhances Central Nervous System Delivery of Bevacizumab for Malignant Glioma Treatment [J].

Liu, Hao-Li ;

Hsu, Po-Hung ;

Lin, Chung-Yin ;

Huang, Chiun-Wei ;

Chai, Wen-Yen ;

Chu, Po-Chun ;

Huang, Chiung-Yin ;

Chen, Pin-Yuan ;

Yang, Liang-Yo ;

Kuo, John S. ;

Wei, Kuo-Chen .

RADIOLOGY, 2016, 281 (01) :99-108

[17]

Logovinsky V, 2016, ALZHEIMERS RES THER, V8, DOI [10.1186/s13195-016-0181-2, 10.1016/j.trci.2016.01.001]

[18] Correlation between elevated levels of amyloid β-peptide in the brain and cognitive decline [J].

Näslund, J ;

Haroutunian, V ;

Mohs, R ;

Davis, KL ;

Davies, P ;

Greengard, P ;

Buxbaum, JD .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2000, 283 (12) :1571-1577

[19] Iduronate-2-Sulfatase with Anti-human Transferrin Receptor Antibody for Neuropathic Mucopolysaccharidosis II: A Phase 1/2 Trial [J].

Okuyama, Torayuki ;

Eto, Yoshikatsu ;

Sakai, Norio ;

Minami, Kohtaro ;

Yamamoto, Tatsuyoshi ;

Sonoda, Hiroyuki ;

Yamaoka, Mariko ;

Tachibana, Katsuhiko ;

Hirato, Tohru ;

Sato, Yuji .

MOLECULAR THERAPY, 2019, 27 (02) :456-464

[20] Are antibodies directed against amyloid- (A) oligomers the last call for the A hypothesis of Alzheimer's disease? [J].

Panza, Francesco ;

Lozupone, Madia ;

Dibello, Vittorio ;

Greco, Antonio ;

Daniele, Antonio ;

Seripa, Davide ;

Logroscino, Giancarlo ;

Imbimbo, Bruno P. .

IMMUNOTHERAPY, 2019, 11 (01) :3-6

← 1 2 3 4 →